Key Drivers
- Strong Liquidity
- Low Leverage
- High Valuation
AIAI Summary
Bio-Techne now looks less like a clean quality compounder and more like a premium-valued franchise that must prove re-acceleration, as strong liquidity and cash flow are being overshadowed by a 2% organic revenue decline, margin-mix pressure, and a sharp post-earnings technical breakdown that leaves limited room for further execution slips.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Low Leverage
- •High Valuation
TECH is financially sound with strong liquidity, low leverage, and solid cash generation, but modest full-year profitability and very demanding valuation multiples make the stock look rich relative to its earnings base.
Price Behavior
Key Price Behavior Insights:
- •Broken base
- •Failed rebound
- •Weak momentum
Over the last month, TECH has been in a clear downtrend, falling about 27% after failing to hold the $51-$55 base, with lower highs/lows and only brief stabilization near $47.4-$48.4.
Sharp drop from $56.68 to $47.41 on 2026-05-06 after a failed rebound
Sentiment & News
Key News Insights:
- •Revenue decline
- •Segment divergence
- •Stock weakness
Bio-Techne's Q3 showed mixed results, with revenue down and the stock falling despite strong performance in key product lines and continued large-pharma growth.
The quarter is likely to keep pressure on Bio-Techne shares until broader biotech spending improves and revenue growth reaccelerates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings